Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder. METHODS: This randomized, double-blind, multicenter, parallel-group trial evaluated dextromethorphan-bupropion versus the active comparator sustained-release bupropion in patients 18-65 years old with a diagnosis of major depressive disorder of moderate or greater severity. Patients were randomly assigned to receive either dextromethorphan-bupropion (45 mg/105 mg tablet) or bupropion (105 mg tablet), once daily for the first 3 days and twice daily thereafter, for a total of 6 weeks. The primary endpoint was overall treatment effect on Montgomery-Åsberg Depression Rating Scale (MADRS) score (average of the change from baseline for weeks 1-6), assessed in all randomized patients whose diagnosis and severity were confirmed by an independent assessor and who received at least one dose of study medication and had at least one postbaseline assessment. RESULTS: Of 97 patients randomized, 17 did not have a confirmed diagnosis and severity based on the independent assessment, resulting in 80 patients in the efficacy population (dextromethorphan-bupropion, N=43; bupropion, N=37). The mean change from baseline in MADRS score over weeks 1-6 (overall treatment effect) was significantly greater with dextromethorphan-bupropion than with bupropion (-13.7 points vs. -8.8 points; least-squares mean difference=-4.9; 95% CI=-3.1, -6.8). MADRS score change with dextromethorphan-bupropion was significantly greater than with bupropion at week 2 and every time point thereafter (week 6: -17.3 vs. -12.1 points; least-squares mean difference=-5.2, 95% CI=-1.1, -9.3). Remission rates were significantly greater with dextromethorphan-bupropion at week 2 and every time point thereafter (week 6: 46.5% vs. 16.2%; least-squares mean difference=30.3%, 95% CI=11.2, 49.4). Response rates (≥50% decrease in MADRS score from baseline) at week 6 were 60.5% with dextromethorphan-bupropion and 40.5% with bupropion (least-squares mean difference=19.9%, 95% CI=-1.6, 41). Most secondary outcomes favored dextromethorphan-bupropion. The most common adverse events with dextromethorphan-bupropion were dizziness, nausea, dry mouth, decreased appetite, and anxiety. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or sexual dysfunction. CONCLUSIONS: In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dextromethorphan’s primary potential for MDD treatment is theorized to be due to its uncompetitive antagonism of the ionotropic glutamate receptor NMDA in the central nervous system [17,18].”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Remission and response rates were significantly higher with dextromethorphan-bupropion in both studies.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“The medication was well-tolerated in both trials, with the most common adverse events being rated as mild-to-moderate.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Changes in Montgomery–Åsberg Depression Rating Scale with dextromethorphan-bupropion were seen within two weeks in both clinical trials.”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
In the citing paper
“Dextromethorphan-bupropion was assessed for efficacy and safety in treating major depressive disorder (MDD) in a phase 2, randomized, double-blind, active-controlled trial (n = 80) [17].”
From Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder (2023) · cites this paper as [17]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Fava, M., & Kendler, K. S. (2000) · Neuron · doi:10.1016/s0896-6273(00)00112-4 · Cited by 603
Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E., Entrena, J., Nieto, F., Cendan, C., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 376
Parsons, C. G., Quack, G., Bresink, I., Baran, L., Przegalinski, E., Kostowski, W., Krzascik, P., Hartmann, S., & Danysz, W. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00092-k · Cited by 311
A Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268
Khin, N. A., Chen, Y.-F., Yang, Y., Yang, P., & Laughren, T. P. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06191 · Cited by 212
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder
Niciu, M. J., Ionescu, D. F., Richards, E. M., & Zarate, C. A. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1130-x · Cited by 177
New targets for rapid antidepressant action
Machado-Vieira, R., Henter, I. D., & Zarate Jr., C. A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.001 · Cited by 154
Rating scales in depression: limitations and pitfalls
Bech, P. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/pbech · Cited by 146
Kobak, K. A., Kane, J., Thase, M. E., & Nierenberg, A. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802eb4b7 · Cited by 123
Pope, L. E., Khalil, M. H., Berg, J. E., Stiles, M., Yakatan, G. J., & Sellers, E. M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004269521 · Cited by 122
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99
Leucht, S., Fennema, H., Engel, R. R., Kaspers–Janssen, M., Lepping, P., & Szegedi, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.12.041 · Cited by 96
Bech, P., Tanghøj, P., Andersen, H. F., & Overø, K. F. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1147-6 · Cited by 91
Khan, A., Bhat, A., Kolts, R., Thase, M. E., & Brown, W. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00151.x · Cited by 78
Reimherr, F. W., Cunningham, L. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · Clinical Therapeutics · doi:10.1016/s0149-2918(98)80060-x · Cited by 72
Murrough, J. W., Stade, E., Sayed, S., Ahle, G., Kiraly, D. D., Welch, A., Collins, K. A., Soleimani, L., Iosifescu, D. V., & Charney, D. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.072 · Cited by 62
Self-citationMancini, M., Wade, A. G., Perugi, G., Lenox‐Smith, A., & Schacht, A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.01.001 · Cited by 32
Thase, M. E., Bowden, C. L., Nashat, M., Eudicone, J. M., Marcus, R. N., McQuade, R. D., & Carlson, B. X. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2011.632680 · Cited by 32
Freeman, M. P., Pooley, J. P., Flynn, M., Baer, L., Mischoulon, D., Mou, D., & D, M. F. M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000669 · Cited by 31
Is it Easier to Find What You Are Looking for if You Think You Know What it Looks Like?
Mundt, J. C., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., DeBrota, D. J., Chappell, P. B., & Modell, J. G. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3180387820 · Cited by 29
Why Are Innovative Drugs Failing in Phase III?
Marder, S. R., LAUGHREN, T. P., & Romano, S. J. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040426 · Cited by 22
Breakthrough-Therapy Designation — An FDA Perspective
Corrigan‐Curay, J., McKee, A. E., & Stein, P. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1801222 · Cited by 22
Salloum, N. C., D, M. F. M., Ball, S., & Papakostas, G. I. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0646-3 · Cited by 18
Research works printed but not linked: 7
- Saltiel PF, 2015, Neuropsychiatr Dis Treat, 11, 875
- World Health Organization, 2018, Fact Sheets: Depression
- Whitlock ME, 2019, Innov Clin Neurosci, 16, 12
- International Conference on Harmonisation, 2001, J Postgrad Med, 47, 45
- First MB, 2015, Structured Clinical Interview for DSM-5 Disorders Clinical Trials Version (SCID-5-CT)
- Davidson JR, 1998, J Clin Psychiatry, 59, 25
- Keefe RS, 2013, Innov Clin Neurosci, 10, 4S
Cited by
New and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 179
Koszła, O., & Sołek, P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01791-8 · Cited by 177
“Additionally, the modified antidepressant drug AXS-05 is in phase III trials and has shown positive effects in treating Sundowner Syndrome in Alzheimer’s patients [117].”
BackgroundQaseem, A., Owens, D. K., Etxeandia‐Ikobaltzeta, I., Tufte, J., Cross, J. T., Wilt, T. J., Crandall, C. J., Balk, E., Cooney, T. G., Fitterman, N., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2056 · Cited by 141
“The CGC is planning to maintain this topic as a living guideline with quarterly literature surveillance and periodic updating of the systematic review and the clinical recommendations, given that the topic is a priority for clinical care and there is active and ongoing research on new and innovative drugs for MDD indi…”
BackgroundCorrell, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., KRAEMER, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 120
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“…quinidine, was investigated in a 2016 phase 2 study for treatment of MDD (NCT02153502); however, the sponsor reported that it halted development of this agent in depression because results of the phase 2 trial did not provide sufficient evidence of efficacy to justify continued development [142].”
BackgroundMethodInfluential
Metadata
- Authors
- Tabuteau, H., Jones, A., Anderson, A., Jacobson, M., & Iosifescu, D. V.
- Affiliations
- Axsome Therapeutics (United States) (US)
- ORCID
- Iosifescu, Dan V.
- Venue
- American Journal of Psychiatry
- Published
- 2022-07-01
- Volume
- 179
- Issue
- 7
- Pages
- 490-499
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4280521929
- Cited by
- 140
- References
- 31
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 33 · 2023: 34 · 2022: 14
- FWCI
- 17.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, NMDA receptor antagonists, sigma-1 receptor agonist, bupropion, CYP2D6 inhibition, glutamatergic neurotransmission, antidepressant efficacy, remission, treatment safety, adverse events, antidepressant drug development
- MeSH terms
- Adolescent, Adult, Aged, Major Depressive Disorder, Depressive Disorder, Major, Dextromethorphan, Double-Blind Method, Humans, Middle Aged, Bupropion, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.